The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu]Lu-DOTATATE

Marco Maccauro, Mariarosaria Cuomo, Matteo Bauckneht, Matteo Bagnalasta, S. Mazzaglia, Federica Scalorbi, Giovanni Argiroffi, Margarita Kirienko, Alice Lorenzoni, G Aliberti, Sara Pusceddu, Giuseppina Calareso, Enrico Matteo Garanzini, Ettore Seregni, Carlo Chiesa